Cargando…

Audit of screen failure in 15 randomised studies from a low and middle-income country

BACKGROUND: Growth and development in patient management occurs via randomised studies. Screen failure is a significant hurdle while conducting randomised studies. There is limited data available from low and middle-income countries about factors resulting in screen failure. Hence, this audit was pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parekh, Deevyashali, Patil, Vijay M, Nawale, Kavita, Noronha, Vanita, Menon, Nandini, More, Sucheta, Goud, Supriya, Jain, Srushti, Mathrudev, Vijayalakshmi, Peelay, Zoya, Dhumal, Sachin, Jogdhankar, Shweta, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934872/ https://www.ncbi.nlm.nih.gov/pubmed/36819805 http://dx.doi.org/10.3332/ecancer.2022.1476

Ejemplares similares

Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer
por: Babanrao Dhumal, Sachin, et al.
Publicado: (2023)

Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation – a randomised trial
por: Patil, Vijay, et al.
Publicado: (2023)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers
por: Peelay, Zoya, et al.
Publicado: (2023)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Lymphopenia during chemoradiation—foe or friend
por: Patil, Vijay M, et al.
Publicado: (2020)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India
por: Patil, Vijay, et al.
Publicado: (2022)

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
por: Joshi, Amit, et al.
Publicado: (2018)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer
por: Shetty, Nishitha, et al.
Publicado: (2015)

Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
por: Patil, Vijay M., et al.
Publicado: (2015)

Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance
por: Patil, Vijay M., et al.
Publicado: (2015)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy
por: Dhumal, Sachin Babanrao, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

Palliative chemotherapy in carcinoma nasopharynx
por: Patil, Vijay M., et al.
Publicado: (2019)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal
por: Joshi, Amit, et al.
Publicado: (2015)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
por: Patil, Vijay M., et al.
Publicado: (2016)

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
por: Khaddar, Satvik, et al.
Publicado: (2022)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Translation and Validation of COST - FACIT (Version 2) Questionnaire into Hindi and Marathi to Assess Financial Toxicity in Indian Cancer Patients
por: Joshi, Amit, et al.
Publicado: (2022)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
por: Patil, Vijay, et al.
Publicado: (2018)

Thyroid cancer in Gardner’s syndrome: Case report and review of literature
por: Punatar, Sachin B, et al.
Publicado: (2012)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
por: Joshi, Amit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s0fe9qphu5udj6qr7g51d3lldi